" class="no-js "lang="en-US"> Mahesh Pratapneni - Medtech Alert
Wednesday, September 27, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Mahesh Pratapneni

Mahesh Pratapneni

About Mahesh Pratapneni

Mahesh (Peema) is an investor, founder, and strategist in the Indian life sciences and technology sectors. He is known for building outstanding global teams, differentiated strategies, and successful exits. He currently serves as Executive Director of MedGenome and is on the boards of AgriGenome Labs, Saksin Life Sciences, Theragen, and Emerge Biologics. Mahesh earned his undergraduate degree in electronics and communications from IIT Madras, and his MBA from IIM Calcutta.

Related Story

Cardiovascular

 Novo Holdings Leads $50 Million Investment in MedGenome to Accelerate Expansion Into New Markets and Deepen Product Offerings | Pharmtech Focus

Novo Holdings Leads $50 Million Investment in MedGenome to Accelerate Expansion Into New Markets and Deepen Product Offerings

August 30 2022

MedGenome, the leading genetic diagnostics, research, and data company in South Asia, announced today a […]